Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
LLY
Eli Lilly and Company
$762.73
Chart
$751.45 (+1.50%)
$826.76 (-7.74%)
$826.76 (-7.74%)
$914.57 (-16.60%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
LLY
Eli Lilly and Company
Current Price
$762.73
Login to view Eli Lilly and Company (LLY) recommendation from the last 90 days from financial news and social media.
Chart
$751.45 (+1.50%)
$826.76 (-7.74%)
$826.76 (-7.74%)
$914.57 (-16.60%)
LLY Latest Analysis
Forecasting The Future: 7 Analyst Projections For Eli Lilly. Providing a diverse range of perspectives from ish to bearish 7 analysts have published ratings on Eli Lilly (NYSE:) in the last three months.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.4201010000000001101021000The 12-month price targets assessed by analysts reveal further insights featuring an average target of $943.
Today
Looking At Eli Lillys Recent Unusual Options Activity. Financial giants have made a conspicuous ish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:) revealed 13 unusual trades.Delving into the details we found 23% of traders were ish while 15% showed bearish tendencies. Out of all the trades we spotted 9 were puts with a value of $609596 and 4 were calls valued at $150651.Based on the trading activity it appears that the significant investors are aiming for a price territ
Today
Eli Lillys $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst. On Tuesday ) agreed to acquire ) a Boston-based clinical-stage company developing genetic .Lilly offered to purchase Verve for $10.50 per share in cash an aggregate of approximately $1.0 billion plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share for a total potential consideration of up to $13.50 per share in cash an aggregate of up to
Wed Jun 18, 2025
Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program.
Tue Jun 17, 2025
Eli Lilly looks beyond its blockbuster obesity drugs with another smart deal. Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Tue Jun 17, 2025
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly. VERV jumps on Eli Lillys buyout offer adding next-gen gene-editing therapies to the pharma giants pipeline.
Tue Jun 17, 2025
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover. Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.The post Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover appeared first on Investor'.s Business Daily.
Tue Jun 17, 2025
Why Verve Therapeutics Stock Is Skyrocketing Today. Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a definitive agreement for Lilly to acquire Verve.
Tue Jun 17, 2025
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion.
Tue Jun 17, 2025
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition. Weight Loss drug maker ) has agreed to acquire ) a Boston-based clinical-stage company developing genetic .Verve’.s lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9 a gene linked to .The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH) a subset of ASCVD that affects 1 in 250 people in the general population as well as c
Tue Jun 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
